检索规则说明:AND代表“并且”;OR代表“或者”;NOT代表“不包含”;(注意必须大写,运算符两边需空一格)
检 索 范 例 :范例一: (K=图书馆学 OR K=情报学) AND A=范并思 范例二:J=计算机应用与软件 AND (U=C++ OR U=Basic) NOT M=Visual
作 者:李爽[1,2] 崔永康[1] 黄兰蔚[1] 周康年[1] 陈锡美[2]
机构地区:[1]上海中医药大学附属曙光医院宝山分院,上海201900 [2]同济大学附属同济医院,上海200065
出 处:《现代中西医结合杂志》2010年第15期1845-1847,共3页Modern Journal of Integrated Traditional Chinese and Western Medicine
摘 要:目的研究胡黄连苦苷Ⅱ对CCl4致大鼠肝纤维化的治疗作用。方法56只大鼠分为正常对照组、模型组、胡黄连苦苷Ⅱ治疗组和胡黄连苦苷Ⅱ对照组,采用CCl4腹腔注射诱导大鼠肝纤维化模型,造模第8周,检测大鼠血清丙氨酸氨基转移酶(ALT)、天冬氨酸氨基转移酶(AST)、白蛋白(ALB)、透明质酸(HA)、层粘连蛋白(LN)、Ⅳ型胶原(Ⅳ-C)、Ⅲ型前胶原(PCⅢ)水平。结果与正常对照组相比,模型组血清ALT、AST、HA、LN、Ⅳ-C、PCⅢ水平显著增高,血清ALB水平显著降低。经胡黄连苦苷Ⅱ干预后,上述指标均显著改善(P<0.01),与正常对照相比较仍有显著性差异(P<0.05)。胡黄连苦苷Ⅱ对照组上述各指标与正常对照组无明显差异(P>0.05)。结论胡黄连苦苷Ⅱ有保护肝细胞、预防CCl4诱导的大鼠肝纤维化作用。Objective It is to investigate the therapeutic effect of Picroside Ⅱ on liver fibrosis induced by carbon tetrachloride(CCl4) in rats.Methods Fifty-six rats were randomly divided into 4 groups: normal control group,model group,Picroside Ⅱ treatment group and Picroside Ⅱ control group.The rat liver fibrosis model was induced by CCl4 administration.At the end of the 8th week,serum alanine aminotransferase(ALT),aspartate amino transferase(AST),albumn(ALB),hyaluronic acid(HA),laminin(LN),collagen IV(IV-C) and type III procollagen(PCIII) were detected.Results Compared with the normal control group,the levels of serum ALT,AST,HA,LN,IV-C and PCIII were significantly increased,and the level of serum ALB significantly was decreased in the model group.After the treatment of Picroside Ⅱ,all the above-mentioned indices were significantly improved(P0.01),and there were significant differences between the Picroside Ⅱ treatment group and the normal control group(P0.05).There was no significant difference in all the above-mentioned indices between the Picroside Ⅱ control group and the normal control group(P0.05).Conclusion Picroside Ⅱ can improve hepatocyte function and inhibit the formation of liver fibrosis induced by CCl4.
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在链接到云南高校图书馆文献保障联盟下载...
云南高校图书馆联盟文献共享服务平台 版权所有©
您的IP:216.73.216.117